Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
